L-BASE
- Biotech or pharma, therapeutic R&D
L-BASE develops autophagy-targeted peptide therapies for drug-resistant cancers. Its lead candidate, LB217, blocks tumor-specific protein CAGE to overcome resistance in EGFR-TKI–refractory NSCLC and other cancers, with strong preclinical data and low toxicity.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}